D9-Tetrahydrocannabinol (THC) Marijuana Studies and
D9-Tetrahydrocannabinol (THC) Cannabis Research
A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. (2006).
Author(s):M. Guzmán, M.J. Duarte, C. Blázquez, J. Ravina, M.C. Rosa, I. Galve-Roperh, C. Sánchez, G. Velasco and L. González-Feria.
Due to its ability to inhibit tumor growth in animals, THC and other cannabinoids have been suggested as antitumor drugs. This is the first clinical study to test the application of THC in human patients with recurrent glioblastoma multiforme. The results demonstrate the safety profile of THC and its action on tumor cells, which establishes the basis for future trials. View study…
Adolescent Exposure to Chronic Delta-9-Tetrahydrocannabinol Blocks Opiate Dependence in Maternally Deprived Rats. (2009).
Author(s):Lydie J Morel, Bruno Giros, and Vale´rie Dauge´,.
THC acts as a homeostatic modifier that worsens the reward effects of morphine in naive animal models, but which would improve deficits in maternal models. This suggests the use of cannabis individuals subjected to an adverse postnatal environment. View study…
Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival. (2010).
Author(s):Jahan P. Marcu, Rigel T. Christian, Darryl Lau, Anne J. Zielinski, Maxx P. Horowitz, Jasmine Lee, Arash Pakdel, Juanita Allison, Chandani Limbad, Dan H. Moore, Garret L. Yount, Pierre-Yves Desprez, and Sean D. McAllister.
Adding cannabidiol to Δ9-THC may improve the effectiveness of Δ9-THC in the treatment of glioblastoma in patients with cancer. When treating the cells with both compounds it was observed that these acted synergistically to inhibit cell proliferation. View study…